论文部分内容阅读
目的探讨顺铂与奈达铂同步放化疗治疗中晚期宫颈癌的临床效果差异。方法 60例中晚期宫颈癌患者,随机分为观察组和对照组,每组30例。观察组采用顺铂同步放化疗,对照组采用奈达铂同步放化疗。评定两组治疗效果和不良反应发生情况。结果观察组有效率与对照组比较,差异无统计学意义(P>0.05)。观察组白细胞减少发生率、肝损伤发生率与对照组比较,差异无统计学意义(P>0.05);观察组血小板降低发生率(23.3%)低于对照组(60.0%),差异有统计学意义(P<0.05)。观察组恶心呕吐发生率(80.0%)高于对照组(40.0%),差异有统计学意义(P<0.05)。观察组肾损伤发生率高于对照组,差异有统计学意义(P<0.05)。结论顺铂与奈达铂同步放化疗治疗中晚期宫颈癌均有显著临床效果,不良反应均可耐受,值得借鉴。
Objective To investigate the clinical effects of cisplatin and nedaplatin simultaneous chemoradiotherapy in the treatment of advanced cervical cancer. Methods Sixty patients with advanced cervical cancer were randomly divided into observation group and control group, 30 cases in each group. The observation group received cisplatin concurrent chemoradiotherapy and the control group received nedaplatin concurrent chemoradiotherapy. Assessment of the two groups of treatment and adverse reactions occurred. Results The effective rate of the observation group compared with the control group, the difference was not statistically significant (P> 0.05). The incidence of leukopenia and the incidence of liver injury in the observation group were not significantly different from those in the control group (P> 0.05). The incidence of thrombocytopenia in the observation group (23.3%) was lower than that in the control group (60.0%), with statistical difference Significance (P <0.05). The incidence of nausea and vomiting in the observation group (80.0%) was higher than that in the control group (40.0%), the difference was statistically significant (P <0.05). The incidence of renal injury in the observation group was higher than that in the control group, with significant difference (P <0.05). Conclusions Both cisplatin and nedaplatin concurrent chemoradiotherapy have a significant clinical effect in the treatment of advanced cervical cancer. The adverse reactions are both tolerable and worth learning from.